Last reviewed · How we verify
Rengalin
At a glance
| Generic name | Rengalin |
|---|---|
| Sponsor | Materia Medica Holding |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children (PHASE3)
- Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rengalin CI brief — competitive landscape report
- Rengalin updates RSS · CI watch RSS
- Materia Medica Holding portfolio CI